4 Perspectives on FDA’s Diversity Action Plan Guidance
Industry leaders share their perspectives on the guidance and how it will affect sponsors moving forward.
In June, the FDA released its Diversity Action Plan guidance. The document outlines requirements for sponsors on submitting diversity plans to the agency. Sponsors of clinical trials must now provide their rationale and goals for patient enrollment—separated by key socioeconomic factors such as ethnicity, sex, and race—and how they intend to meet those goals.
In a press release from the time of when the guidance was announced, FDA Commissioner Robert M. Califf, MD, said, “The agency’s draft guidance is an important step—and one of many ongoing efforts—to address the participation of underrepresented populations in clinical trials to help improve the data we have about patients who will use the medical products if approved.”
Since the key announcement, Applied Clinical Trials has spoken with several industry leaders on how this guidance will impact sponsors. In this slideshow, Del Smith, PhD, co-founder & CEO of Acclinate; Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit share their perspectives on one of FDA’s latest initiatives to increase diversity in clinical trials.
Image Credit: © Jakub Krechowicz - stock.adobe.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
